Page last updated: 2024-10-25

cimetidine and Pharyngeal Neoplasms

cimetidine has been researched along with Pharyngeal Neoplasms in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Pharyngeal Neoplasms: Tumors or cancer of the PHARYNX.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Perl, A1
Gonzalez-Cabello, R1
Benedek, K1
Nékam, K1
Láng, I1
Gergely, P1

Other Studies

1 other study available for cimetidine and Pharyngeal Neoplasms

ArticleYear
Effect of histamine-receptor blocking on human natural and lectin-dependent cell-mediated cytotoxicity against adherent HEP-2 cells.
    Thymus, 1985, Volume: 7, Issue:2

    Topics: Cell Adhesion; Cell Line; Cimetidine; Clemastine; Concanavalin A; Cytotoxicity, Immunologic; Histami

1985